Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 39 entries
View as:

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

Phase: N/A Priority: Normal
NCT ID: NCT06506994 Org: User:
Start: 07/15/24 End: 10/20/24 Due: 10/20/25

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT06425341 Org: User:
Start: 06/06/24 End: 01/19/27 Due: 01/19/28

A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06541457 Org: User:
Start: 08/15/24 End: 05/31/25 Due: 05/31/26

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05893576 Org: User:
Start: 05/15/23 End: 09/04/23 Due: 09/04/24

A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06732154 Org: User:
Start: 11/28/24 End: 02/28/26 Due: 02/28/27

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06054698 Org: User:
Start: 10/31/23 End: 09/30/24 Due: 09/30/25

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05509634 Org: User:
Start: 09/21/22 End: 08/30/23 Due: 08/30/24

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05152277 Org: User:
Start: 12/06/21 End: 08/24/22 Due: 08/24/23

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06246175 Org: User:
Start: 02/28/24 End: 07/31/24 Due: 07/31/25

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05966272 Org: User:
Start: 08/12/23 End: 09/24/24 Due: 09/24/25

A Trial of HRS-7450 in Chinese Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06087094 Org: User:
Start: 10/31/23 End: 12/31/23 Due: 12/31/24

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06723691 Org: User:
Start: 12/18/24 End: 06/09/25 Due: 06/09/26

A Study of Remimazolam Tosilate for Sedation in the ICU

Phase: N/A Priority: Normal
NCT ID: NCT05152303 Org: User:
Start: 10/12/22 End: 04/19/23 Due: 04/19/24

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Phase: N/A Priority: Normal
NCT ID: NCT06194201 Org: User:
Start: 04/27/24 End: 06/30/26 Due: 06/30/27

Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05465681 Org: User:
Start: 08/30/22 End: 01/13/23 Due: 01/13/24

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06435676 Org: User:
Start: 06/04/24 End: 10/08/24 Due: 10/08/25

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06595797 Org: User:
Start: 09/30/24 End: 12/31/25 Due: 12/31/26

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Phase: N/A Priority: Normal
NCT ID: NCT06554184 Org: User:
Start: 09/03/24 End: 09/01/25 Due: 09/01/26

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT06447415 Org: User:
Start: 08/06/24 End: 06/17/25 Due: 06/17/26

A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Phase: N/A Priority: Normal
NCT ID: NCT06934408 Org: User:
Start: 04/30/25 End: 04/30/26 Due: 04/30/27

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT05881837 Org: User:
Start: 06/13/23 End: 10/13/24 Due: 10/13/25

Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06506175 Org: User:
Start: 08/05/24 End: 11/30/24 Due: 11/30/25

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Phase: N/A Priority: Normal
NCT ID: NCT06974851 Org: User:
Start: 05/31/25 End: 12/31/26 Due: 12/31/27

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

Phase: N/A Priority: Normal
NCT ID: NCT06650007 Org: User:
Start: 11/08/24 End: 07/31/26 Due: 07/31/27

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Phase: N/A Priority: Normal
NCT ID: NCT06396429 Org: User:
Start: 05/13/24 End: 08/30/25 Due: 08/30/26